Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Medpace Holdings Inc(MEDP)
Top performer 
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for MEDP
11/11/2026: MEDP (5-star) is a STRONG-BUY. BUY for 107 days. Simulated Profits (39.93%). Updated daily EoD!
Medpace Holdings Inc is a specialized clinical research organization known for its physician-led approach to managing complex drug development trials. The company maintains a leading position by focusing on high-growth, small-to-mid-sized biotechnology sponsors, which has historically resulted in strong operating margins. Its primary growth story involves the increasing trend toward outsourced R&D and the company's ability to offer integrated laboratory and clinical services. However, the company faces risks from its cyclical dependence on biotech funding and competition from larger, scale-oriented rivals. The stock is a fit for growth-oriented investors, while its lack of a dividend may make it less suitable for income-focused portfolios.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company maintains a strong record of scaling operations and capturing market share in the growing outsourced clinical trial sector. |
| Momentum investor | Strong fit while signal remains positive | MEDP has historically demonstrated strong price performance trends consistent with investor interest in high-growth healthcare services. |
| Value investor | Mixed fit | While profitable and disciplined, the stock typically commands a valuation premium reflecting its growth prospects, which may deter traditional value investors. |
| Dividend investor | Weak fit | Medpace does not pay a dividend, making it unsuitable for investors seeking current income. |
| Low-risk investor | Mixed fit | The reliance on biotech funding cycles introduces cyclical risk and stock price volatility that may exceed the tolerance of low-risk investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | The stock is susceptible to fluctuations based on the broader biotech funding environment and healthcare sector sentiment. |
| Valuation risk | Medium | Strong growth expectations are priced into the stock, leaving little margin for error in quarterly earnings performance. |
| Competition risk | Medium | Larger incumbents like IQV possess deeper technology resources that could challenge Medpace’s market share in specific segments. |
| Business quality | Strong | The company has a proven, disciplined, physician-led business model that has consistently generated high returns. |
| Dividend income | Low / none | No dividend is paid, requiring investors to rely entirely on capital appreciation. |
| Execution risk | Medium | Successful trial management requires precise execution, and any regulatory or data failure could impact the company's reputation and business. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 111.05% | Avg. Invested days 53 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/11/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Sector & Industry Intelligence
Sector snapshot as of 2026-11-10
Sector
Healthcare
- Signal
- Constructive
- Sentiment
- Strong Bullish
- Market state
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 60.0%
- Active BUY / eligible
- 69 / 115
- 22-session BUY-count change
- +29
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Diagnostics & Research
- BUY participation
- 68.8%
- Active BUY / eligible
- 11 / 16
- 22-session BUY-count change
- -1
The sector signal does not change this stock’s BUY, SELL, or PASS advisory.
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 18.59B USD | Price to earnings Ratio 36.9 | 1Y Target Price 651.31 |
Price to earnings Ratio 36.9 | 1Y Target Price 651.31 | ||
Volume (30-day avg) 297.6K shares | Beta 1.11 | 52 Weeks Range 373.00 - 693.97 | Updated Date 11/11/2026 |
52 Weeks Range 373.00 - 693.97 | Updated Date 11/11/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 18.01 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development Services | Fees earned for managing clinical trials, including patient recruitment, monitoring, and data management for pharmaceutical and biotech clients. | This is the primary revenue engine, growing as sponsors outsource more of their complex medical studies. |
| Laboratory and Ancillary Services | Revenues from central lab testing, bioanalysis, and medical imaging services integrated into clinical trials. | These high-margin services provide essential data for clinical trials and act as a sticky value-add for clients. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2026-10-21 | When After Market | Estimate 4.45 | Actual 4.84 |
Profitability
Profit Margin 18.24% | Operating Margin (TTM) 23.12% |
Management Effectiveness
Return on Assets (TTM) 18.71% | Return on Equity (TTM) 117.88% |
Valuation
Trailing PE 36.9 | Forward PE 34.13 | Enterprise Value 18.26B | Price to Sales(TTM) 6.55 |
Enterprise Value 18.26B | Price to Sales(TTM) 6.55 | ||
Enterprise Value to Revenue 6.44 | Enterprise Value to EBITDA 28.8 | Shares Outstanding 27.97M | Shares Floating 22.73M |
Shares Outstanding 27.97M | Shares Floating 22.73M | ||
Percent Insiders 18.66 | Percent Institutions 88.83 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.